1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63B8E52CCFF4FDE4D85258473003C2FEE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/3B8E52CCFF4FDE4D85258473003C2FEE?OpenDocument
18
19OpenDocument
203.234.214.179
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Marketing Management Patient Advocacy

Document Excerpt: Patient Advocacy 2020: Use of Technology, Current Trends & Future Directions in the United States

DB Image

ID: MD-678


Features:

16 Info Graphics

4 Data Graphics

50+ Metrics

7 Narratives


Pages/Slides: 4


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5578 "Patient Advocacy 2020: Use of Technology, Current Trends & Future Directions in the United States”.

Industries Profiled:
Biopharmaceutical; Biotech; Communications; Pharmaceutical; Medical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Acceleron Pharma; Agendia; Alnylam Pharmaceuticals; Amicus Therapeutics; ApotheCom; Astellas; AveXis; AVROBIO; Baldwin Area Medical Center; Bayer; Biogen; Blue Earth Diagnostics; Boehringer Ingelheim; CRISPR Therapeutics; Daiichi Sankyo; Dermira; Forum Pharmaceuticals; Grifols; GlaxoSmithKline ; Genzyme; Horizon Pharma; Incyte; Ipsen; Janssen; Johnson & Johnson; Lexicon Pharmaceuticals; Mallinckrodt; Milestone Pharmaceuticals; Natera; Novartis; Novo Nordisk; OTSUKA; Pfizer; Pharmacyclics; Reata Pharmaceuticals; Retrophin; Sage Therapeutics; Spark Therapeutics; Theravance; Ultragenyx; Wave Life Sciences; Zimmer Biomet; Zogenix

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.